Tuberculous uveitis is a rare condition caused by Mycobacterium tuberculosis. Involvement of the uveal tract is the most common manifestation of the disease, and findings of granulomatous anterior uveitis, disseminated choroiditis with vitritis, and cystoid macular edema are common. Diagnosis requires a high level of suspicion for the disease as systemic signs and symptoms of infection may not be present and is made by exclusion of other causes of uveitis. Treatment involves multidrug antimicrobial therapy in combination with topical and oral corticosteroids.
- 1 Disease Entity
- 2 Diagnosis
- 3 Management
- 4 Additional Resources
- 5 References
Tuberculous Uveitis ICD9 364.11
Currently ocular involvement of tuberculosis (TB) is a rare condition in the United States diagnosed in only 1-2% of patients. In the developing world incidence of systemic disease is much higher with over 8 million new cases each year, and incidence of TB uveitis mirrors this rate. At major referral centers in India the incidence of tuberculous uveitis ranged from 0.6% to 10%; similarly, in Japan and Saudi Arabia rates were 7.9% to 10.5%. This contrasts with an incidence rate of 0.6% at a large tertiary care facility in the United States. However, while overall rates are still low in the US, incidence of tuberculosis has increased simultaneously with the commencement of the AIDS epidemic. In the immunocompromised population, rates of extrapulmonary TB have increased. In addition, foreign-born individuals represent nearly half of the case in the US and are another emerging population of new patients with this disease entity.
Most commonly the infection is limited to pulmonary involvement with only 20% having extrapulmonary disease. Extrapulmonary disease is often seen in severely immunocompromised patients or those with HIV/AIDS. A small minority of infected patients develop symptomatic disease generally in the first 1-2 years.
Mycobacterium tuberculosis is the acid-fast-staining obligate aerobe responsible for the disease, which is characterized by granuloma formation. It is transmitted most commonly via aerosolized droplets. Organisms are commonly found in lung apices as the organism has an affinity for highly oxygenated tissue. This is the same reason organisms infect the choroid as this tissue has the highest blood flow rate in the body.
Recent exposure can cause primary systemic infection and, more commonly, reactivation of latent disease causes secondary infection. Patients who are immunocompromised from chronic disease, HIV/AIDS, or medication; health care workers; and recent immigrants from endemic areas are high-risk populations.
Bacilli invade tissue and a delayed type hypersensitivity reaction develops, causing caseous necrosis and tubercle. Infection spreads throughout the body when bacteria-laden macrophages carry the organism to different sites. Ziehl-Neelson acid-fast stain can be used to visualize bacteria within granulomas.
Tuberculosis can affect the eye either primarily with active infection or secondarily as a result of immune reaction to the mycobacterium. The conjunctiva, cornea, and sclera are sites of primary ocular involvement. Hematogenous spread of the disease or spread from neighboring structures is responsible for uveitis which is the most common manifestation of secondary ocular TB. Ocular manifestations of TB are varied and include scleritis, phlyctenulosis, interstitial keratitis, corneal infiltrates, anterior chamber and iris nodules, and granulomatous anterior uveitis. These can occur without signs of systemic involvement.
Primary prevention for tuberculous uveitis involves prevention of exposures to actively infected individuals, in order to prevent systemic infection.
Diagnosis if tuberculous uveitis is often one of exclusion as identification of the mycobacteria in ocular tissue or aqueous humor is not always possible. Laboratory and diagnostic testing pointing to systemic TB infection aids in diagnosing presumptive TB uveitis as well as serologic testing to rule out other causes of uveitis.
The time of onset, duration of symptoms, and a thorough review of systems are necessary, and patients should be questioned regarding fevers, night sweats, chronic pulmonary infection and weight loss to assess for systemic involvement because extrapulmonary infection can present with these classic symptoms as well. A history of travel to endemic areas or prior exposure to an acutely infected individual should also be elicited. Immunosuppressive medications taken for another process need to be documented and addressed.
Blurry vision, and light sensitivity may be the only reported symptoms. Other complaints may include headache, redness of the eye, floaters, or flashes. Patients may also be asymptomatic.
Anterior segment examination should be done to evaluate for granulomatous anterior uveitis. Mutton-fat keratic precipitates, iris or angle granulomas, posterior synechiae, hypopyon and secondary glaucoma may be present. Panuveitis and intermediate uveitis are possible. Posterior uveitis with disseminated choroiditis is the most common manifestation of tuberculous uveitis, and is often bilateral. Multiple, discrete, yellow lesions uni- or bilaterally may be seen in the posterior pole ranging from pinpoint to several disc diameters in size. As lesions progress their borders may become more distinct with a rim of surrounding black pigment and the center becomes paler or turns yellow leading to an atrophic scar. Subretinal neovascularization can later develop. Disc edema, periphlebitis, vasculitis, and vitritis can be present. Large single tuberculomas may be found with or without associated retinal detachment and macular star formation. Infection can also present as multifocal choroiditis or serpiginous-like choroiditis and caseous liquefaction of choroidal granlomas can lead to subretinal abscesses.
The diagnosis of tuberculosis uveitis requires a combination of patient history, clinical examination and adjunct testing.
Usually , the diagnosis of IOTB is presumptive after excluding other possible uveitis entities. As suggested by Guta V. et al the difinite (confirmed) diagnosis of intraocular T.B. requires the following :
- One or more clinical signs that are suggestive of TB
- One of the following ocular investigatioons needs to be positive
- Demonstration of AFB by microscope or culture of M. tuberculosis from the ocular fluids.
- Positive polymerase chain reaction from ocular fluids.
Because that is always difficult to be obtained , the diagnosis of IOTB is almost always presumptive. For presumed intraocular T.B. Abu El-Asrar et al and Gupta V. et al in their reviews of intraocular T.B. have defined presumed intraocuar T.B as the following :
- Ocular findings consistent with possible intraocular TB with no other cause of uveitis suggested by history of symptoms, or ancillary testing.
- Strongly positive tuberculin skin test results (≥15 mm area of induration/necrosis) , radiological evidence of healed or active tubercular lesion in the chest or evidence of cnfirmed active extrapulmonary T.B. either by microscopic examination or by culture from affected tissue.
- Response to antituberculous therapy with absence of recurrences.
Fluorescein angiography reveals early hyperfluorescence of active choroidal lesions and late leakage. Cicatricial lesions show early blocked hyperfluorescence with late staining. Indocyanine green angiography shows early and late stage hypofluorescence of the lesions and subclinical lesions may be seen.
Ultrasonography reveals moderate to low internal reflectivity of large tuberculomas and can distinguish them from intraocular malignancy.
Laboratory work up includes testing to rule out other causes for uveitis as well as PPD skin testing and chest x-ray and/or chest CT. A positive PPD skin test indicates prior exposure and not necessarily active infection. Half of patients with extrapulmonary involvement can have a negative chest x-ray and 20% can have a negative purified protein derivative skin test. Also, false negative PPD results occur 25% of the time in those with immunocompromise. Prior history of Bacille Calmette-Guerin (BCG) vaccination causes false-positives.
The Quantiferon-Gold test, an interferon gamma release assay, was developed in 2007 to aid in the diagnosis of tuberculosis and is recommended for use as an alternative to tuberculin skin testing by the United States Centers for Disease Control and Prevention. Because diagnosis of tuberculosis-related uveitis is often difficult because of complicating factors such as prior BCG vaccination, immunosuppression, and low yield of aqueous fluid cultures in diagnosis, the use of Quantiferton-Gold testing has been found to be useful in increasing the confidence in a diagnosis when skin test results are indeterminate or inconsistent with clinical findings. However, negative Quantiferon-Gold testing does not necessarily rule out a diagnosis of tuberculous uveitis and repeat testing may be necessary.
Negative testing for systemic disease still does not rule out ocular involvement. Intraocular fluid analysis or tissue biopsy would make a definitive diagnosis in these cases; however, this is not always available. Diagnosis can be made with nucleic acid amplification by either transcription-mediated amplification of 16S RNA or PCR amplification of DNA sequences of the mycobacteria. Chorioretinal biopsy has been used to make the diagnosis as well and can be used with nucleic acid amplification techniques.
Differential diagnosis includes other etiologies for uveitis including histoplasmosis, toxocariasis, sarcoidosis, syphilis, toxoplasmosis, and acute retinal necrosis. Tuberculomas may resemble melanoma or retinoblastoma.
The treatment of tuberculosis uveitis involves treatment of the underlying infection, whether it manifests as pulmonary or disseminated systemic disease. Ocular therapy alone is not curative and may mask expression of the disease symptoms; however, it may be used in conjunction with systemic therapy to treat the ocular manifestations and prevent the ocular sequelae of chronic uveitis.
For patients with suspected tuberculous uveitis systemic multi-drug antibiotic therapy is necessary due to the prevalence of multidrug-resistant tuberculosis and they should be managed in conjunction with an infectious disease specialist. In addition to antimicrobial therapy, topic and oral corticosteroids are frequently used. Use of steroids necessitates the use of antituberculous therapy concurrently as ocular disease will worsen on steroids alone.
Medical follow up
There are no exact guidelines for duration of treatment of ocular TB. Generally at least 9 months of therapy are required. CDC recommendations include prolonged therapy for any sites that are unresponsive.
Surgical intervention is often limited to diagnostic procedures such as diagnostic vitrectomy or chorioretinal biopsy.
Persistent inflammation may lead to secondary glaucoma, cataract formation, and cystoids macular edema, the most common cause of visual loss in uveitis. Anti-tuberculous treatments themselves may contribute to ocular complications. Ethambutol can lead to a dose-related optic neuritis, color vision deficiencies, central scotomas, and even retinal edema and foveal pigmentary changes. These effects are usually present after 3-6 months of treatment and necessitate frequent examinations especially for those patients on more than 15 mg/kg/day. Isoniazid has less commonly been reported to cause an optic neuritis as well. Rifabutin side effects include a severe acute anterior uveitis with hypopyon.
Without treatment there is a waxing and waning course of disease with eventual degradation of the blood-aqueous barrier and increased vitreous opacities and cystoid macular edema. It is possible to have sclera necrosis and performation if the disease process involves the sclera. With the initiation of anti-tuberculous therapy prognosis is good and choroidal lesions can resolve completely. Serpiginous-like choroiditis has a poorer prognosis with little response to antituberculous therapy or corticosteroids.
- Intraocular Inflammation and Uveitis, Section 9. Basic and Clinical Science Course, AAO, 2006.
- Gupta V, Gupta A, and Rao N. Intraocular tuberculosis – an update. Surv Ophthalmol 2007; 52: 561-587.
- Albini T, Karakousis, and Rao N. Interferon-gamma release assays in the diagnosis of tuberculous uveitis. Am J Ophthalmol 2008; 146(4): 486-488.
- Ang M, Htoon H, and Chee S. Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. Opthalmol 2009; 116: 1391-1396.
- Abu El-Asrar AM, Abouammoh M, Al-Mezaine HS. Tuberculous uveitis. Middle East Afr J Ophthalmol 2009;16:188-201